JUPITER-06 establishes immune checkpoint inhibitors as essential first-line drugs for the treatment of advanced esophageal squamous cell carcinoma
-
Published:2022-03
Issue:3
Volume:40
Page:238-240
-
ISSN:1535-6108
-
Container-title:Cancer Cell
-
language:en
-
Short-container-title:Cancer Cell
Author:
Yamamoto Shun,Kato Ken
Subject
Cancer Research,Oncology
Reference10 articles.
1. Updated analysis and patient-reported outcomes from CITYSCAPE: a randomised, double-blind, Phase II study of the anti-TIGIT antibody tiragolumab + atezolizumab vs placebo + atezolizumab as first-line treatment for PD-L1+ NSCLC;Cho;Ann. Oncol.,2021
2. Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma;Doki;N. Engl. J. Med.,2022
3. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial;Kato;Lancet Oncol.,2019
4. Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer;Kelly;N. Engl. J. Med.,2021
5. Randomized phase III KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer;Kojima;J. Clin. Oncol.,2020
Cited by
16 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献